1. Home
  2. PZG vs MGNX Comparison

PZG vs MGNX Comparison

Compare PZG & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paramount Gold Nevada Corp.

PZG

Paramount Gold Nevada Corp.

HOLD

Current Price

$1.96

Market Cap

97.2M

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.08

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PZG
MGNX
Founded
1992
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.2M
115.8M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
PZG
MGNX
Price
$1.96
$3.08
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.40
AVG Volume (30 Days)
1.2M
1.3M
Earning Date
01-01-0001
06-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$330,259.00
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$0.99
52 Week High
$2.70
$3.50

Technical Indicators

Market Signals
Indicator
PZG
MGNX
Relative Strength Index (RSI) 40.60 73.39
Support Level $1.05 $1.45
Resistance Level $2.54 $3.50
Average True Range (ATR) 0.14 0.22
MACD -0.08 0.10
Stochastic Oscillator 2.86 75.44

Price Performance

Historical Comparison
PZG
MGNX

About PZG Paramount Gold Nevada Corp.

Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: